Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $52.76M. The enterprise value is $69.30M.

Cue Biopharma has 75,349,884 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -181.74%.

The current PE Ratio of Cue Biopharma is -1.51. Cue Biopharma’s PEG ratio is -0.39.

In the last 12 months, Cue Biopharma had revenue of 9.29M and earned -40.67M in profits. Earnings per share was -0.72.

In the last 12 months, operating cash flow was -34.72M and capital expenditures -161.00K, giving a free cash flow of -34.88M billion.

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Cue Biopharma upcoming earnings date is Sep 8, 2025, TBA (Confirmed).

Cue Biopharma as a current ratio of 1.84, with Debt / Equity ratio of 29.41%

In the past 12 months, Cue Biopharma has paid 0.00 in taxes.

Cue Biopharma EV to EBITDA ratio is -1.15, with an EV/FCF ratio of -1.31.

Cue Biopharma has $13.14M in cash and marketable securities with $7.13M in debt, giving a net cash position of -$6.01M billion.

Gross margin is -45.04%, with operating margin of -446.86%, and net profit margin of -437.97%.

The average price target for Cue Biopharma is $1.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy